All News

A new oral hair loss pill just cleared phase 2/3 trials. Study investigator Michael Gold, MD, breaks down how VDPHL01 compares to minoxidil and finasteride.

ECHO-based menopause education improved PCP confidence and revealed gaps in sexual health, bleeding, and weight management training, according to new research.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.

6-month INFUSE data show eptinezumab improves migraine outcomes, including headache days and patient-reported measures, even after prior CGRP failures.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

The FDA cleared Tandem's Control-IQ+ as the first AID system approved for pregnancy in type 1 diabetes, backed by the CIRCUIT trial.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

WHO’s 2025 kidney health resolution pushes nations to spot CKD earlier, bolster primary care treatment, and expand dialysis and transplant access.

Two-year CAHtalyst Adult data show crinecerfont enabled sustained glucocorticoid dose reductions while maintaining androgen control in classic CAH.

Phase 3 data show IL‑33 antibody tozorakimab cuts COPD flare-ups across smokers and low eosinophils, hinting a new biologic option.

Amoxicillin shows similar efficacy to amoxicillin-clavulanate for acute sinusitis, with fewer adverse events, supporting first-line use.

The TRIDENT trial shows a once-daily triple BP pill after intracerebral hemorrhage improves control and lowers recurrent stroke and cardiovascular events.

FDA approves doravirine/islatravir for adults with virologically suppressed HIV-1, offering a once-daily 2-drug regimen with noninferior efficacy.

Steven Nissen, MD, discusses new SURPASS-CVOT data showing reduced cardiorenal events and mortality with tirzepatide vs dulaglutide.

Real-world data show zuranolone improved postpartum depression symptoms by Day 15 with sustained benefit through Day 45.

A new executive order aims to speed up FDA access to psychedelic therapies; psychiatrist Gus Alva, MD, reviews evidence, safety risks, and more.

A secondary analysis of the FINEARTS-HF trial demonstrated consistent treatment efficacy in patients with and without a history of IHD. Details from study author Jawad Butt, MD, here.

ACP guidance recommends biennial mammography for women aged 50-74 and shared decision-making for screening in women aged 40-49.